BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors (Q33528294)

27 July 2017

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors (English)

1 reference

27 July 2017

0 references

1 reference

Erika Graf

2

0 references

Marcus O. Pinsker

5

object named as

Marcus O Pinsker

1 reference

27 July 2017

Thomas Reithmeier

1

1 reference

27 July 2017

Tobias Piroth

3

1 reference

27 July 2017

Michael Trippel

4

1 reference

27 July 2017

Guido Nikkhah

6

1 reference

27 July 2017

language of work or name

English

0 references

publication date

2 February 2010

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

30

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-30

27 July 2017

0 references

cites work

Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Recurrent glioblastoma multiforme: a review of natural history and management options

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Targeted modulation of MGMT: clinical implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Novel radiation-enhancing agents in malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Practical guidelines for the treatment of malignant gliomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Reoperation in the treatment of recurrent intracranial malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Management of malignant glioma: steady progress with multimodal approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-30

High activity iodine-125 interstitial implant for gliomas

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837009

Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20122270

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-10-30

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference